{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:59:37Z","timestamp":1785394777329,"version":"3.55.0"},"reference-count":74,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Small-cell lung cancer (SCLC) is broadly classified into limited- (LS) and extensive-stage (ES) disease, with distinct therapeutic approaches and outcomes. Despite high initial response rates, most patients eventually experience disease progression, particularly in the ES setting, where effective treatment options remain limited. For several decades, platinum\u2013etoposide-based chemotherapy has remained the cornerstone of treatment, with modest improvements in overall survival. Recent advances in cancer immunology have led to the incorporation of immune checkpoint inhibitors as the first-line treatment for many cancers, representing the first major therapeutic breakthrough for SCLC. In ES-SCLC, the addition of programmed death-ligand 1 (PD-L1) inhibitors to platinum\u2013etoposide chemotherapy has become the standard first-line approach based on the survival benefits demonstrated in phase III trials. In LS-SCLC, a consolidation PD-L1 inhibitor following definitive chemoradiotherapy has recently emerged as a new standard, as highlighted by the ADRIATIC trial, which demonstrated a significant survival advantage with durvalumab. Despite these advances, the prognosis of ES-SCLC remains poor with limited response durability and lack of robust predictive biomarkers. Tumor heterogeneity, dynamic phenotypic plasticity, and the absence of actionable genomic alterations continue to hinder precision treatment strategies. In relapse settings, novel antibody-based therapies have begun to reshape the therapeutic landscape. Delta-like ligand 3 (DLL3)-targeted T-cell engagers and antibody\u2013drug conjugates directed against DLL3 and B7-H3 have shown encouraging antitumor activity in heavily pretreated patients, with some agents advancing to late-phase clinical evaluations. This review summarizes the systemic therapies for SCLC, focusing on recent advances in immunotherapy and emerging antibody-based strategies. This review discusses current challenges, including treatment resistance, toxicity, and biomarker development, and highlights future perspectives aimed at enabling more personalized and effective therapeutic approaches for patients with this historically aggressive disease.<\/jats:p>","DOI":"10.1177\/17588359261466640","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:40:23Z","timestamp":1785148823000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy and the novel therapeutic development for small-cell lung cancer"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6143-1205","authenticated-orcid":false,"given":"Midori","family":"Matsuo","sequence":"first","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan"},{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2414-8344","authenticated-orcid":false,"given":"Hirokazu","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Clinical Oncology Center, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan"},{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Takemoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Mine","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawana","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Akagi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"},{"name":"Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Tomono","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritaka","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6105-2670","authenticated-orcid":false,"given":"Yosuke","family":"Dotsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Ashizawa","sequence":"additional","affiliation":[{"name":"Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29098"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.4859"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1191920"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.1548"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1061"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.4905"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/1758834013517413"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e328011a547"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2008.0027"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30098-5"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.5069"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.071"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.161.5.1135"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.2.265"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0753-2"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.207"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3727\/096504018X15202953107093"},{"issue":"4","key":"e_1_3_4_20_2","article-title":"Surgery for limited-stage small-cell lung cancer","volume":"4","author":"Barnes H","year":"2017","unstructured":"Barnes H, See K, Barnett S, et al. Surgery for limited-stage small-cell lung cancer. Cochrane Database Syst Rev 2017; 4(4): CD011917.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2020.03.79"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02295-w"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01806"},{"key":"e_1_3_4_24_2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): small cell lung cancer. Version 1.2024. Plymouth Meeting (PA): National Comprehensive Cancer Network. https:\/\/www.nccn.org (2023 accessed 27 April 2026)."},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.12.006"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404873"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.03.034"},{"key":"e_1_3_4_28_2","unstructured":"Placebo-controlled phase 3 study of concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab with or without olaparib in LS-SCLC. Japan Registry of Clinical Trials https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCT2031200296 (2021 accessed 27 April 2026)."},{"key":"e_1_3_4_29_2","unstructured":"Phase 3 study of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer. Japan Registry of Clinical Trials https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCT2021240012 (2024 accessed 27 April 2026)."},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01569"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02462-y"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt178"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.282"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.7918"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30539-8"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01011-6"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00480-2"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0133-9"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.12.014"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02014-x"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.07.008"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.01.010"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31824c7f4b"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0026"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.658"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.5821"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.3998"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0028-1"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02489-2"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307980"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502099"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00914-x"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1020"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado4618"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110814"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2059"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.7672"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.10.021"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107216"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.04.026"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1680921"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0286"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.009"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2026.103726"},{"issue":"1","key":"e_1_3_4_68_2","article-title":"ADC for SCLC clears phase I","volume":"16","author":"American Association for Cancer Research","year":"2026","unstructured":"American Association for Cancer Research. ADC for SCLC clears phase I. Cancer Discov 2026; 16(1): OF1.","journal-title":"Cancer Discov"},{"key":"e_1_3_4_69_2","unstructured":"A phase 1b\/2 study of I-DXd in combination with atezolizumab with or without carboplatin in first-line ES-SCLC (IDeate-Lung03). Japan Registry of Clinical Trials. Available at: https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCT2031240089 (2024 accessed 27 April 2026)."},{"key":"e_1_3_4_70_2","unstructured":"Phase 3 study of GSK5764227 in participants with relapsed small cell lung cancer (SCLC). Japan Registry of Clinical Trials https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCT2071250052 (2025 accessed 27 April 2026)."},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1547"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2016.09.002"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8129"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.01.041"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01363"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261466640","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261466640","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261466640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:18:05Z","timestamp":1785392285000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261466640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":74,"alternative-id":["10.1177\/17588359261466640"],"URL":"https:\/\/doi.org\/10.1177\/17588359261466640","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17588359261466640"}}